

Primary Driver in the Phesgo Market 2025: Rising Incidence Of Breast Cancer Driving The Growth Of The Market

*The Business Research Company's Phesgo
Market Report 2025 – Market Size,
Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, February 6, 2025
/EINPresswire.com/ -- Updated 2025
Market Reports Released: Trends,
Forecasts to 2034 – Early Purchase
Your Competitive Edge Today!

The logo for The Business Research Company, featuring the text "The Business Research Company" in a black, sans-serif font. To the right of the text is a stylized bar chart with three bars of varying heights, colored in shades of green and teal.

The Business
Research Company

Phesgo Market Report 2025 – Market Size, Trends,
And Global Forecast 2025-2034

Is the [Phesgo Market](#) Set to Witness Substantial Growth?

Driven by a rising awareness of HER2-positive breast cancer, an expanding variety of HER2-targeted therapies, along with sizable pharmaceutical industry investments, government healthcare initiatives, and favorable reimbursement policies, the Phesgo market has demonstrated considerable annual growth in recent years. Moving from a sizeable \$XX million in 2024, the market is envisaged to reach \$XX million by 2025, growing at an impressive compound annual growth rate CAGR of XX%.

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample_request?id=20347&type=smp

Looking ahead, the Phesgo market is not showing any signs of slowing down. On the contrary, it is expected to display an even more impressive growth rate over the next years thanks to a host of contributing factors. The expanding biologics sector, growth in healthcare infrastructure, rising use of combination therapies, the growing preference for targeted therapies, a rising focus on patient-centered care, and an increasing focus on subcutaneous biologics are all expected to play a major part in pushing the market size even higher to an expected \$XX million by 2029, at a CAGR of XX%.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/phesgo-global-market-report>

What Drives The [Phesgo Market Growth](#)?

The key drivers behind the Phesgo market's significant growth are multifaceted. Among the foremost is the rising number of breast cancer incidents across various regions. Breast cancer, a type of cancer that begins in the milk ducts or lobules of the breasts, is increasing due to aging populations, lifestyle changes, genetic predisposition, environmental exposures, and hormonal influences. These factors significantly contribute to this health concern which has a knock-on effect on the demand for medications such as Phesgo. Delivering a convenient fixed-dose combination of pertuzumab and trastuzumab, Phesgo helps delay tumor growth and progression by targeting the HER2 protein.

A perfect illustration of this driver is evident in the alarmingly rising number of new breast cancer cases in the United States. According to a study by the American Cancer Society, there was a substantial increase from 300,590 in 2023 to 313,510 in 2024, stimulating a corresponding demand for effective treatments such as Phesgo.

Who Are The Key Players In The Phesgo Market?

Playing a pivotal role in the Phesgo market are major companies like F. Hoffmann-La Roche AG and Chugai Pharmaceutical Co. Ltd. These industry players have an influential part in shaping the market trends and contributing to its progress.

What Are The Emerging Trends In The Phesgo Market?

A key trend currently shaping the Phesgo market is the introduction of innovative therapies such as monoclonal antibody combination therapy. These therapies have the potential to significantly enhance the treatment efficacy and improve patient outcomes in oncology, thereby providing an even more compelling case for their use. An excellent illustration of this trend is Chugai Pharmaceutical's November 2023 launch of the Phesgo combination for Subcutaneous Injection MA, IN. This innovative treatment combines pertuzumab and trastuzumab, two monoclonal antibodies, with hyaluronidase to offer a highly effective treatment for HER2-positive breast cancer and advanced HER2-positive colorectal cancer.

How Is The Phesgo Market Segmented?

Understanding the Phesgo market also requires an accurate grasp of its segmentation. The market is divided into specific areas for a thorough exploration.

- 1 By Indication: Early Breast Cancer; Metastatic Breast Cancer
- 2 By Formulation: Subcutaneous Injection; Intravenous Infusion
- 3 By Distribution Channel: Direct Sales; Online Pharmacies; Wholesale Distributors
- 4 By End User: Hospitals; Oncology Clinics; Home Healthcare

Regional Analysis Of Phesgo Market:

When studying the dynamics of regional markets, North America took the lead as the largest Phesgo market region in 2024. As we move forward, Asia-Pacific is expected to dominate as the fastest-growing region. The comprehensive Phesgo market report covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and

Africa.

Discover more exciting insights through similar reports by [The Business Research Company](#).

Breast Cancer Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report>

Breast Cancer Diagnostics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report>

Breast Cancer Monoclonal Antibodies Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/breast-cancer-monoclonal-antibodies-global-market-report>

About The Business Research Company

With an extensive collection of 15000+ reports spanning 27 industries across 60+ geographies, The Business Research Company has carved a distinct reputation for delivering comprehensive, data-intensive research and insights. With our team's rich secondary research experience, access to 1,500,000 datasets, and industry leaders' exclusive insights, we ensure you stay ahead in your industry.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/783551079>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.